The initial adoption of anti–PD-1/PD-L1 monotherapy as first-line treatment for advanced NSCLC in the US quickly shifted to combination anti–PD-1/PD-L1 therapy with platinum-based chemotherapy between 2016 and 2020. The gene discussed is CD274; the disease is non-small cell lung carcinoma.